Warning letter
Miami University Department of Chemistry and Biochemistry: warning letter of Apr 20, 2022
FDA warning letter 623494 · Pharmaceutical Quality Operations Division III
Key facts
| Reference number | 623494 |
|---|---|
| Company | Miami University Department of Chemistry and Biochemistry |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Apr 20, 2022 |
| Posted date | May 3, 2022 |
| Issuing office | Pharmaceutical Quality Operations Division III |
| Product type | Drugs |
| Inspection city | Oxford |
| Inspection ZIP | 45056 |
| Inspection start date | Nov 1, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: